This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 8
  • /
  • Forxiga approved in Japan for the treatment of chr...
News

Forxiga approved in Japan for the treatment of chronic kidney disease

Read time: 1 mins
Published:26th Aug 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).

The approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) is based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the MHLW earlier this year. CKD is a serious, progressive condition defined by decreased kidney function and is often associated with an increased risk of heart disease or stroke.The condition affects 840 million people worldwide. However, diagnosis rates remain low and up to 90% of patients are unaware they have the disease. Forxiga is the first ever approved medicine for the treatment of the disease in Japan.

Condition: Chronic Kidney Disease/CKD
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.